Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York, Buffalo, NY 14260, USA.
J Pharmacol Exp Ther. 2011 Dec;339(3):896-904. doi: 10.1124/jpet.111.185686. Epub 2011 Sep 8.
Type 2 diabetes mellitus (T2DM) arises owing to insulin resistance and β-cell dysfunction. Chronic inflammation is widely identified as a cause of T2DM. The Goto-Kakizaki (GK) rat is a spontaneous rodent model for T2DM with chronic inflammation. The purpose of this study was to characterize diabetes progression in GK rats and evaluate the potential role of the anti-inflammatory agent salsalate. The GK rats were divided into control groups (n = 6) and salsalate treatment groups (n = 6), which were fed a salsalate-containing diet from 5 to 21 weeks of age. Blood glucose and salicylate concentrations were measured once a week. Glucose concentrations showed a biphasic increase in which the first phase started at approximately 5 weeks, resulting in an increase by 15 to 25 mg/dl and a second phase at 14 to 15 weeks with an upsurge of more than 100 mg/dl. A mechanism-based model was proposed to describe the natural diabetes progression and salsalate pharmacodynamics by using a population method in S-ADAPT. Two transduction cascades were applied to mimic the two T2DM components: insulin resistance and β-cell dysfunction. Salsalate suppressed both disease factors by a fraction of 0.622 on insulin resistance and 0.134 on β-cell dysfunction. The substantial alleviation of diabetes by salsalate supports the hypothesis that chronic inflammation is a pathogenic factor of diabetes in GK rats. In addition, body weight and food intake were measured and further modeled by a mechanism-based growth model. Modeling results suggest that salsalate reduces weight gain by enhancing metabolic rate and energy expenditure in both GK and Wister-Kyoto rats.
2 型糖尿病(T2DM)是由于胰岛素抵抗和β细胞功能障碍引起的。慢性炎症被广泛认为是 T2DM 的病因之一。Goto-Kakizaki(GK)大鼠是一种自发性 2 型糖尿病伴慢性炎症的啮齿动物模型。本研究旨在描述 GK 大鼠的糖尿病进展,并评估抗炎剂柳氮磺胺吡啶的潜在作用。将 GK 大鼠分为对照组(n = 6)和柳氮磺胺吡啶治疗组(n = 6),从 5 至 21 周龄给予含柳氮磺胺吡啶的饮食。每周测量一次血糖和水杨酸盐浓度。血糖浓度呈双峰增加,第一阶段约在 5 周开始,增加 15 至 25mg/dl,第二阶段在 14 至 15 周,增加超过 100mg/dl。采用基于群体的 S-ADAPT 方法,通过建立数学模型来描述自然糖尿病进展和柳氮磺胺吡啶药效动力学,提出了一个机制模型。该模型应用了两个转导级联来模拟 2 型糖尿病的两个组成部分:胰岛素抵抗和β细胞功能障碍。柳氮磺胺吡啶通过对胰岛素抵抗的分数 0.622 和对β细胞功能障碍的分数 0.134 来抑制这两个疾病因素。柳氮磺胺吡啶对糖尿病的显著缓解支持了慢性炎症是 GK 大鼠糖尿病发病机制的致病因素这一假说。此外,还测量了体重和食物摄入量,并通过基于机制的生长模型进一步建模。建模结果表明,柳氮磺胺吡啶通过提高代谢率和 GK 大鼠和 Wister-Kyoto 大鼠的能量消耗来减轻体重增加。